Skip to main content
Top
Published in: Journal of Neural Transmission 5/2018

01-05-2018 | Psychiatry and Preclinical Psychiatric Studies - Original Article

Kynurenine is correlated with IL-1β in plasma of schizophrenia patients

Authors: Helena P. G. Joaquim, Alana C. Costa, Wagner F. Gattaz, Leda Leme Talib

Published in: Journal of Neural Transmission | Issue 5/2018

Login to get access

Abstract

The etiology of schizophrenia is still unclear. It is well-known that pro-inflammatory cytokines are higher in schizophrenia patients since the first episode psychosis comparing to healthy controls. Inflammatory downstream cascades influence different cellular pathways, like the displacement of the tryptophan (TRP) metabolism to the production of kynurenine (KYN) instead of serotonin, which results in the generation of several neuro and immunoactive metabolites. The aim of this study was to determine TRP, KYN and IL-1β plasma levels in first-onset schizophrenia (n = 28) and healthy controls (n = 30). The plasmatic levels of TRP and KYN were decreased in schizophrenic patients (p = 0.004 and p = 0.002, respectively), but there was no difference in the ratio of KYN/TRP (p = 0.554) or either in IL-1β (p = 0.101). Positive correlation was observed between KYN and IL-1β only in the schizophrenia group (r = 0.461, p = 0.021). And, there was also positive correlation between KYN and Positive and Negative Symptoms Scale (PANSS) (r = 0.395, p = 0.037). There is no correlation between the other analytes and other parameters of PANSS. Although our results of KYN have been different than expected and there was no difference in the KYN/TRP ratio, we observed a positive correlation between IL-1β and KYN, corroborating findings that pro-inflammatory agents hold up the KYN pathway.
Literature
go back to reference Barry S, Clarke G, Scully P, Dinan TG (2009) Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 23:287–294CrossRefPubMed Barry S, Clarke G, Scully P, Dinan TG (2009) Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol 23:287–294CrossRefPubMed
go back to reference Bramon E, Sham PC (2001) The common genetic liability between schizophrenia and bipolar disorder: a review. Curr Psychiatry Rep 3:332–337CrossRefPubMed Bramon E, Sham PC (2001) The common genetic liability between schizophrenia and bipolar disorder: a review. Curr Psychiatry Rep 3:332–337CrossRefPubMed
go back to reference Brown AS, Susser ES (2002) In utero infection and adult schizophrenia. Ment Retard Dev Disabil Res Rev 8:51–57CrossRefPubMed Brown AS, Susser ES (2002) In utero infection and adult schizophrenia. Ment Retard Dev Disabil Res Rev 8:51–57CrossRefPubMed
go back to reference Dounay AB, Tuttle JB, Verhoest PR (2015) Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J Med Chem 58:8762–8782CrossRefPubMed Dounay AB, Tuttle JB, Verhoest PR (2015) Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J Med Chem 58:8762–8782CrossRefPubMed
go back to reference Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E et al (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 163:521–528CrossRefPubMed Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E et al (2006) Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 163:521–528CrossRefPubMed
go back to reference Erhardt S, Oberg H, Mathé JM, Engberg G (2001) Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20:353–362CrossRefPubMed Erhardt S, Oberg H, Mathé JM, Engberg G (2001) Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 20:353–362CrossRefPubMed
go back to reference Erhardt S, Schwieler L, Imbeault S, Engberg G (2017) The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology 112:297–306CrossRefPubMed Erhardt S, Schwieler L, Imbeault S, Engberg G (2017) The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology 112:297–306CrossRefPubMed
go back to reference Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, Ulivieri M, Napoletano F, Capo M, Corigliano V, Scaccionoce S, Caruso A, Miele J, De Fusco A, Di Menna L, Comparelli A, De Carolis A, Grandini R, Nistico R, De Blasi A, Girardi P, Bruno V, Battaglia G, Nicoletti F, Simmaco M (2015) Xanthurenic acid activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep 5:17799CrossRefPubMedPubMedCentral Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, Ulivieri M, Napoletano F, Capo M, Corigliano V, Scaccionoce S, Caruso A, Miele J, De Fusco A, Di Menna L, Comparelli A, De Carolis A, Grandini R, Nistico R, De Blasi A, Girardi P, Bruno V, Battaglia G, Nicoletti F, Simmaco M (2015) Xanthurenic acid activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep 5:17799CrossRefPubMedPubMedCentral
go back to reference Fillman SG, Cloonan N, Miller LC, Weickert CS (2013) Markers of inflammation in the prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18:133CrossRefPubMed Fillman SG, Cloonan N, Miller LC, Weickert CS (2013) Markers of inflammation in the prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 18:133CrossRefPubMed
go back to reference First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR axis I disorders. Research version. Non-patient edition (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute, New York First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR axis I disorders. Research version. Non-patient edition (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute, New York
go back to reference Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, Seishima M (2006) The signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 139:655–662CrossRefPubMed Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, Seishima M (2006) The signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 139:655–662CrossRefPubMed
go back to reference Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007–2017CrossRefPubMed Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007–2017CrossRefPubMed
go back to reference Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Ursonomiya M, Nakatani M, Sadamoto K, Yoshio T (2014) Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One 9:101652CrossRef Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, Nishikiori M, Seki A, Ichiba H, Watanabe Y, Hongo S, Ursonomiya M, Nakatani M, Sadamoto K, Yoshio T (2014) Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One 9:101652CrossRef
go back to reference Gal EM, Sherman AD (1980) l-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 5:223–239CrossRefPubMed Gal EM, Sherman AD (1980) l-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res 5:223–239CrossRefPubMed
go back to reference Garver DL, Tamas RL, Holcomb JÁ (2003) Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 28:1515–1520CrossRefPubMed Garver DL, Tamas RL, Holcomb JÁ (2003) Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 28:1515–1520CrossRefPubMed
go back to reference Haber R, Bessette D, Hulihan-Giblin B, Durcan MJ, Goldman D (1993) Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J Neurochem 60:1159–1162CrossRefPubMed Haber R, Bessette D, Hulihan-Giblin B, Durcan MJ, Goldman D (1993) Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J Neurochem 60:1159–1162CrossRefPubMed
go back to reference Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463–7473CrossRefPubMed Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463–7473CrossRefPubMed
go back to reference Jospeh MH, Baker HF, Crow TJ, Riley GJ, Risby D (1979) Brain tryptophan metabolism in schizophrenia: a post mortem study of metabolites of the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology 62:279–285CrossRefPubMed Jospeh MH, Baker HF, Crow TJ, Riley GJ, Risby D (1979) Brain tryptophan metabolism in schizophrenia: a post mortem study of metabolites of the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology 62:279–285CrossRefPubMed
go back to reference Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale for schizophrenia. Schizophr Bull 13:261–276CrossRefPubMed Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale for schizophrenia. Schizophr Bull 13:261–276CrossRefPubMed
go back to reference Kegel ME, Svensson CI, Erhardt S (2011) IL-1 induces IDO and TDO transcription and provokes the release of kynurenic acid from human astrocytes in vitro. Progr No 24019/E7 Neurosci Meet Planner Washington, DC. Soc Neurosci Online Kegel ME, Svensson CI, Erhardt S (2011) IL-1 induces IDO and TDO transcription and provokes the release of kynurenic acid from human astrocytes in vitro. Progr No 24019/E7 Neurosci Meet Planner Washington, DC. Soc Neurosci Online
go back to reference Lake CR, Hurwitz N (2007) Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease—there is no schizoaffective disorder. Curr Opin Psychiatry 20:365–379CrossRefPubMed Lake CR, Hurwitz N (2007) Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease—there is no schizoaffective disorder. Curr Opin Psychiatry 20:365–379CrossRefPubMed
go back to reference Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373:234–239CrossRefPubMed Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373:234–239CrossRefPubMed
go back to reference Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, Samuelsson M, Erhardt S (2012) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 38:426–432CrossRefPubMed Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, Samuelsson M, Erhardt S (2012) Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 38:426–432CrossRefPubMed
go back to reference Mándi Y, Vécsei L (2012) The kynurenine system and immunoregulation. J Neural Transm 119:197–209CrossRefPubMed Mándi Y, Vécsei L (2012) The kynurenine system and immunoregulation. J Neural Transm 119:197–209CrossRefPubMed
go back to reference Miller CL, Llenos IC, Dulay JR, Weis S (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1074:25–37CrossRef Miller CL, Llenos IC, Dulay JR, Weis S (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1074:25–37CrossRef
go back to reference Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S, Steinbusch HW, Leonard BE, Kim YK (2011) Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 25:1576–1581CrossRefPubMed Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S, Steinbusch HW, Leonard BE, Kim YK (2011) Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 25:1576–1581CrossRefPubMed
go back to reference Okusaga O, Fuchs D, Reeves G, Giegling I, Hartmann AM, Konte B, Friedl M, Groer M, Cook TB, Stearns-Yoder KA, Pandey JP, Kelly DL, Hoisington AJ, Lowry CA, Eaton WW, Brenner LA, Rujescu D, Postolache TT (2016) Kynurenine and tryptophan levels in patients with schizophrenia and elevated antigliadin immunoglobulin G antibodies. Psychosom Med 78:931–939CrossRefPubMedPubMedCentral Okusaga O, Fuchs D, Reeves G, Giegling I, Hartmann AM, Konte B, Friedl M, Groer M, Cook TB, Stearns-Yoder KA, Pandey JP, Kelly DL, Hoisington AJ, Lowry CA, Eaton WW, Brenner LA, Rujescu D, Postolache TT (2016) Kynurenine and tryptophan levels in patients with schizophrenia and elevated antigliadin immunoglobulin G antibodies. Psychosom Med 78:931–939CrossRefPubMedPubMedCentral
go back to reference Owen MJ, Craddock N (2009) Diagnosis of functional psychoses: time to face the future. Lancet 373:190–191CrossRefPubMed Owen MJ, Craddock N (2009) Diagnosis of functional psychoses: time to face the future. Lancet 373:190–191CrossRefPubMed
go back to reference Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G, Graff-Guerrero A (2017) Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 43:764–777CrossRefPubMed Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G, Graff-Guerrero A (2017) Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 43:764–777CrossRefPubMed
go back to reference Raison CL, Miller AH (2004) Brain–immune system interaction: relevance to the pathophysiology and treatment of neuropsychiatric disorders. In: Schatzberg AF, Nemeroff CB (eds) The American psychiatric publishing textbook of psychopharmacology, 3rd edn. American Psychiatric Press, Washington, pp 147–162 Raison CL, Miller AH (2004) Brain–immune system interaction: relevance to the pathophysiology and treatment of neuropsychiatric disorders. In: Schatzberg AF, Nemeroff CB (eds) The American psychiatric publishing textbook of psychopharmacology, 3rd edn. American Psychiatric Press, Washington, pp 147–162
go back to reference Rao JS, Kim HW, Harry GJ, Rapoport SI, Reese EA (2013) Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res 147:24–31CrossRefPubMed Rao JS, Kim HW, Harry GJ, Rapoport SI, Reese EA (2013) Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res 147:24–31CrossRefPubMed
go back to reference Ravikumar A, Deepadevi KV, Arun P, Manojkumar V, Kurup PA (2000) Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol India 48:231–238PubMed Ravikumar A, Deepadevi KV, Arun P, Manojkumar V, Kurup PA (2000) Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol India 48:231–238PubMed
go back to reference Saito K, Crowley JS, Markey SP, Heyes MP (1993) A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem 268:15496–15503PubMed Saito K, Crowley JS, Markey SP, Heyes MP (1993) A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem 268:15496–15503PubMed
go back to reference Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, Yoshida S, Arima K, Higuchi T, Amano N, Kunugi H (2013) Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 47:401–406CrossRefPubMed Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, Yoshida S, Arima K, Higuchi T, Amano N, Kunugi H (2013) Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 47:401–406CrossRefPubMed
go back to reference Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, Schwarcz R (2011) Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 37:1147–1156CrossRefPubMed Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, Schwarcz R (2011) Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 37:1147–1156CrossRefPubMed
go back to reference Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521–530CrossRefPubMed Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521–530CrossRefPubMed
go back to reference Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, Finn A, Bhat M, Samuelsson M, Lundberg K, Dahl ML, Sellgren C, Schuppe-Koistinen I, Svensson C, Erhardt S, Engberg G (2015) Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci 40:126–133PubMedPubMedCentral Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, Finn A, Bhat M, Samuelsson M, Lundberg K, Dahl ML, Sellgren C, Schuppe-Koistinen I, Svensson C, Erhardt S, Engberg G (2015) Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia-significance for activation of the kynurenine pathway. J Psychiatry Neurosci 40:126–133PubMedPubMedCentral
go back to reference Sellgren CM, Kegel ME, Bergen SE, Ekman CJ, Olsson S, Larsson M, Vawter MP, Backlund L, Sullivan PF, Sklar P, Smoller JW, Magnusson PK, Hultman CM, Walther-Jallow L, Svensson CI, Lichtenstein P, Schalling M, Engberg G, Erhardt S, Landén M (2016) A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol Psychiatry 21:1342–1350CrossRefPubMed Sellgren CM, Kegel ME, Bergen SE, Ekman CJ, Olsson S, Larsson M, Vawter MP, Backlund L, Sullivan PF, Sklar P, Smoller JW, Magnusson PK, Hultman CM, Walther-Jallow L, Svensson CI, Lichtenstein P, Schalling M, Engberg G, Erhardt S, Landén M (2016) A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol Psychiatry 21:1342–1350CrossRefPubMed
go back to reference Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, Erhardt S, Engberg G (2009) Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 14:1069–1107CrossRefPubMedPubMedCentral Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, Erhardt S, Engberg G (2009) Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 14:1069–1107CrossRefPubMedPubMedCentral
go back to reference Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309–379PubMed Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309–379PubMed
go back to reference Stone TW, Forrest CM, Mackay GM, Stoy N, Darlington LG (2007) Tryptophan, adenosine, neurodegeneration and neuroprotection. Metab Brain Dis 22:337–352CrossRefPubMed Stone TW, Forrest CM, Mackay GM, Stoy N, Darlington LG (2007) Tryptophan, adenosine, neurodegeneration and neuroprotection. Metab Brain Dis 22:337–352CrossRefPubMed
go back to reference Upthegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155:101–108CrossRefPubMed Upthegrove R, Manzanares-Teson N, Barnes NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res 155:101–108CrossRefPubMed
go back to reference Vécsei L, Szalárdy L, Fülöp F, Toldi J (2013) Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12:64–82CrossRefPubMed Vécsei L, Szalárdy L, Fülöp F, Toldi J (2013) Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12:64–82CrossRefPubMed
go back to reference Wonodi I, Schwarcz R (2010) Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 36(2):211–218CrossRefPubMedPubMedCentral Wonodi I, Schwarcz R (2010) Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull 36(2):211–218CrossRefPubMedPubMedCentral
Metadata
Title
Kynurenine is correlated with IL-1β in plasma of schizophrenia patients
Authors
Helena P. G. Joaquim
Alana C. Costa
Wagner F. Gattaz
Leda Leme Talib
Publication date
01-05-2018
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 5/2018
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-018-1838-8

Other articles of this Issue 5/2018

Journal of Neural Transmission 5/2018 Go to the issue

Neurology and Preclinical Neurological Studies - Review Article

Let’s make microglia great again in neurodegenerative disorders

Neurology and Preclinical Neurological Studies - Review Article

Neuroinflammatory responses in Alzheimer’s disease

Neurology and Preclinical Neurological Studies - Original Article

Interleukin 6 and complement serum level study in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Review Article

The IL-1β phenomena in neuroinflammatory diseases